Consistent with previous studies, our study also failed to show the significant prolongation of OS in the patients treated with ChemoIO compared with those without ChemoIO; thus, ChemoIO (including ABCP) is still not a standard treatment for EGFR-mutant lung cancer. This evidence concerns the gene EGFR and lung cancer.